Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
International Journal of Hematology
Published in: International Journal of Hematology 3/2019

01-03-2019 | Chronic Lymphocytic Leukemia | Letter to the Editor

Ibrutinib in Japanese patients with relapsed/refractory B-cell malignancies: final analysis of phase I study

Authors: Kensei Tobinai, Toshiki Uchida, Noriko Fukuhara, Tomoaki Nishikawa

Published in: International Journal of Hematology | Issue 3/2019

Login to get access

Excerpt

A phase I, open-label, dose-escalation study (first human study of ibrutinib in Japan) assessed the safety and antitumor activity of single-agent ibrutinib in Japanese patients with relapsed/refractory mature B-cell malignancies (RRBCM) (NCT01704963). The primary analysis was reported previously [1]. Here we report the final analysis; median duration of follow-up was 32.4 months (range 5.1–48.8). …
Literature
1.
Tobinai K, Ogura M, Ishizawa K, Suzuki T, Munakata W, Uchida T, et al. Safety and tolerability of ibrutinib monotherapy in Japanese patients with relapsed/refractory B cell malignancies. Int J Hematol. 2016;103:86–94.CrossRefPubMed
Metadata
Title
Ibrutinib in Japanese patients with relapsed/refractory B-cell malignancies: final analysis of phase I study
Authors
Kensei Tobinai
Toshiki Uchida
Noriko Fukuhara
Tomoaki Nishikawa
Publication date
01-03-2019
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 3/2019
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-018-02577-8

Other articles of this Issue 3/2019

International Journal of Hematology 3/2019 Go to the issue

Case Report

Complete remission of pure white cell aplasia associated with thymoma after thymectomy and cyclosporine administration

Review Article

Hematopoietic stem cell transplantation in primary central nervous system lymphoma: a review of the literature

Correction

Correction to: Neuronopathic Gaucher disease presenting with microcytic hypochromic anemia

Images in Hematology

Tuberculous lymphadenitis mimicking Castleman disease-like histological features

Original Article

Decline of forced expiratory volume in 1 s after allogeneic hematopoietic cell transplantation is a good indicator for pulmonary damage and is associated with busulfan use

Case Report

Neuronopathic Gaucher disease presenting with microcytic hypochromic anemia
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits